Reproductive · In Clinical Trials
Carbetocin
No lawful US pathway
01 · Overview
A long-acting synthetic analog of oxytocin with structural modifications that confer resistance to enzymatic degradation. Carbetocin has a longer half-life and greater receptor selectivity than oxytocin (PMID 42486751).
It binds oxytocin receptors in the myometrium, promoting uterine contraction and reducing postpartum blood loss, and a heat-stable formulation does not require cold-chain storage.
02 · Research summary & key findings
Not FDA-approved in the United States; it is used in other countries, and heat-stable carbetocin is among the WHO-recommended drugs for postpartum hemorrhage prevention being introduced in low- and middle-income countries (PMID 42260007). The WHO CHAMPION trial (Widmer et al., NEJM, 2018) of nearly 30,000 women found heat-stable carbetocin noninferior to oxytocin for preventing blood loss of at least 500 mL after vaginal birth, although noninferiority was not shown for blood loss of at least 1000 mL (PMID 29949473). A meta-analysis of cesarean deliveries in low-risk women found carbetocin reduced the need for additional uterotonics and blood transfusion compared with oxytocin (PMID 39722234). An intranasal formulation failed to beat placebo for hyperphagia in Prader-Willi syndrome in the phase 3 COMPASS PWS study (PMID 42486751).
03 · Regulatory status
Carbetocin is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Carbetocin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 9 FDA-approved compounds in Reproductive
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for hormone optimization?
Carbetocin is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intravenous
- Intramuscular injection
References
- [1]Heat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth N Engl J Med, 2018. PMID 29949473
- [2]A systematic review and meta-analysis of randomized trials comparing carbetocin to oxytocin in prevention of postpartum hemorrhage after cesarean delivery in low-risk women J Obstet Gynaecol Res, 2025. PMID 39722234
- [3]Role of professional associations in the drive for policy change and uptake of new WHO recommendations for the prevention and treatment of postpartum hemorrhage Int J Gynaecol Obstet, 2026. PMID 42260007
- [4]Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS Study Clin Ther, 2026. PMID 42486751
Primary literature
- PubMed: "Carbetocin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Carbetocin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Carbetocin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Reproductive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.